Document is current
Any future updates will be listed below
-
Authors
Salaroglio, I. C.
Aviles, P.
Kopecka, J.
Merlini, A.
Napoli, F.
Righi, L.
Novello, S.
Sullivan, H.
Cuevas, C.
Scagliotti, G. V.
Riganti, C. https://orcid.org/0000-0001-9787-4836
-
Funding
Funding for this research was provided by:
Associazione Italiana per la Ricerca sul Cancro (IG21408, IG29250, IG23760)
Fondazione Cassa di Risparmio di Torino (2018.0568, 2021.05556)
Ministero dell’Istruzione, dell’Università e della Ricerca (PNRR PNC - D3 4 HEALTH)
- License Information
-
More Information
Article History
Received: 1 October 2024
Accepted: 6 December 2024
First Online: 21 December 2024
Declarations
:
: The study was approved by the local Ethical Committee (#128/2016). The patients gave written informed consent to participate in the study.
: The patients gave written informed consent to publish the results of the study.
: PA, HS and CC are PharmaMar S.A. employees or Pharma-Mar S.A. shareholders or both. CR received lurbinectedin and its derivatives, and economical support from PharmaMar S.A. AM received travel expense reimbursement from PharmaMar S.A. outside the present work and is member of the advisory board of Boehringer Ingelheim. LR received grants from AstraZeneca, Roche, Eli Lilly, and Novartis outside the submitted work. SN is speaker’s bureau for: Amgen, AstraZeneca, Boehringer Ingelheim, BeiGene, Eli Lilly, Pfizer, Roche, MSD, Janssen, Novartis, Takeda, Thermo Fisher, member of the advisory board and consultant for Sanofi. GVS has received grants from TESARO/GSK and personal fees as well as supports from Pfizer, AstraZeneca, Eli Lilly and MSD outside the submitted work; personal fees from Roche, Novartis, Clovis, Takeda and BeiGene outside the submitted work.
